GGrantIndex
← Leaderboards

David C Musch

University Of Michigan At Ann Arbor

$2,966,828
Attributed
$3,297,953
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $434.2K · FY200522
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$3,297,953 · 8

By mechanism

R21$2,148,557 · 5
R03$459,000 · 1
D43$457,146 · 1
R34$233,250 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Vision

Research focus

VisionReportingGlaucomaVisual FieldsBaseVisual ImpairmentMedicalNational Eye InstituteClinical TrialsData AnalysesApplications GrantsResearch PersonnelNewly DiagnosedOpen-Angle GlaucomaInsightRisk FactorsEye DiseasesVisualMonitorAffectCharacteristicsClinically RelevantBlindnessClinical Research

Grant awards (15)

Building Non-Communicable Eye Disease Research Capacity in India$223,594
D43 · FY2022 · TW · contact PI
Building Non-Communicable Eye Disease Research Capacity in India$233,552
D43 · FY2021 · TW · contact PI
Assessing the Interplay of Vision with Cognitive Functioning, Balance, and Falls in Middle-aged Women$234,000
R21 · FY2020 · EY · contact PI
Glaucoma progression ? Modeling its trajectory and contributing factors: evidence from AGIS and CIGTS$239,202
R21 · FY2019 · EY · contact PI
Assessing the Interplay of Vision with Cognitive Functioning, Balance, and Falls in Middle-aged Women$195,000
R21 · FY2019 · EY · contact PI
Glaucoma progression ? Modeling its trajectory and contributing factors: evidence from AGIS and CIGTS$202,855
R21 · FY2018 · EY · contact PI
Assessing the impact of glaucoma and its treatment on the person$232,500
R21 · FY2016 · EY · contact PI
Assessing the impact of glaucoma and its treatment on the person$193,750
R21 · FY2015 · EY · contact PI
Statins To Prevent Progression of Glaucoma: The STOP Glaucoma Trial$233,250
R34 · FY2013 · EY
Insights on Glaucoma from Analysis of the CIGTS Data$193,125
R21 · FY2012 · EY · contact PI
Insights on Glaucoma from Analysis of the CIGTS Data$233,250
R21 · FY2011 · EY · contact PI
Clinical and Quality of Life Insights on Glaucoma from Analyses of CIGTS Data$193,125
R21 · FY2009 · EY · contact PI
Clinical and Quality of Life Insights on Glaucoma from Analyses of CIGTS Data$231,750
R21 · FY2008 · EY · contact PI
Analysis of CIGTS Visual Field Data$229,500
R03 · FY2005 · EY
Analysis of CIGTS Visual Field Data$229,500
R03 · FY2004 · EY